Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf حسب Kristin R. Anderson (5478734)

The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The ANCOVA and Post_hoc results. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

CONSORT flowchart. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

Time to stabilization in the vertical direction. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The description of games. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The description of balance training. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The flow-diagram for the randomised clinical study. حسب Iva Milinkovic (22331710)

الموضوعات:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. حسب Denis Mustafov (19137870)

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

The Human Disharmony Loop Clinical Presentation. حسب James M. Friedman (22522150)

الموضوعات:

Clinical and epidemiological characteristics. حسب Domingos L. S. Rios (20496173)

"…However, large studies providing a comprehensive longitudinal observation of patients undergoing this therapy are lacking. We evaluated the effectiveness of treating severe obesity in hospitalized patients, using very low-calorie diets and clinical support to develop lifestyle changes. …"

General characteristics and clinical data of the subjects included in the study. حسب Spela Kokelj (8356644)

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Pre-RT and post RT D-dimer levels in associated with prognostic significance. حسب Huriye Senay Kiziltan (22298378)

الموضوعات:

Participant retention flowchart. حسب Carolin Oetzmann (11397968)

"…These same classes were identified at 6- and 12-month follow-ups, and participants tended to remain in the same class over time. We found no statistically significant differences between the two severe subtypes regarding baseline clinical and sociodemographic characteristics. …"

Details of the GWAS data in this study. حسب Jing Wang (6206297)

الموضوعات:

Side effect. حسب My Tra Thi Nguyen (22120541)

"…<div><p>Background</p><p>This study aimed to evaluate the clinical effectiveness of bilastine in type IIb autoimmune CSU (type IIb aiCSU) patients over an 8-week period, as well as to identify factors predicting treatment response.…"